Set Targets Not Price Limits, German Industry Pleads
Plans for reference-price group for four anti-TNFs, including adalimumab and etanercept
Grouping together biosimilar adalimumabs and etanercepts with patented biologics in the same reference-price group in Germany threatens to remove biosimilars’ market advantage and weaken competition, local industry fears.
You may also be interested in...
Switching German patients from one biologic to another without involving their doctor could cause patients to perceive biosimilars as having inferior safety and efficacy, a local physicians’ body is warning.
Plans for substituting biological drugs at pharmacy level that have been passed by Germany’s lower house of parliament threaten to undo the good work done to date in winning trust in biosimilars, local industry association Pro Biosimilars fears.
Germany’s off-patent industry association, Pro Generika, is finding ample support for its position that by awarding tender contracts to exclusive suppliers, health insurance funds are contributing to drug shortages in the country.